Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hackensack Meridian Health
National Cancer Institute (NCI)
Thomas Jefferson University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Brown University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Scripps Translational Science Institute
Washington University School of Medicine
City of Hope Medical Center
Thomas Jefferson University
Thomas Jefferson University
Takeda
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Pfizer
Emory University
OHSU Knight Cancer Institute
University of Nebraska
Virginia Commonwealth University
Amgen
Bristol-Myers Squibb
University of Michigan Rogel Cancer Center